Page 1

EX - 99.1 2 eypt - ex991_6.htm EX - 99.1 EYEPOINT PHARMACEUTICALS Exhibit 99.1 EyePoint Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments Positive 30 - Day Safety Data Reported for EYP - 1901 DAVIO study for the potential treatment of wet AMD ; study remains on track for initial readout in Q4 2021 -Net product revenues of $ 8.7 million versus $ 3.7 million in Q2 2020 , a 136 % increase ; - Management to host a conference call and webcast today at 8:30 AM ET – WATERTOWN , Mass . , August 4 , 2021 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals , Inc. ( NASDAQ : EYPT ) , a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders , today announced financial results for the second quarter ended June 30 , 2021 and highlighted recent corporate developments . " We made significant progress in Q2 with our Phase 1 DAVIO trial for EYP - 1901 and we substantially grew our net product revenue to $ 8.7M , a 136 % increase vs Q2 2020. Most importantly , we continue to seamlessly execute our Phase 1 DAVIO trial and have achieved several important milestones , starting with the dosing of the first patient in January , the completion of enrollment in May , and our announcement of positive 30 - day safety data in July . We remain on track and look forward to providing top line six - month interim safety and efficacy data in the fourth quarter of this year , " said Nancy Lurker , Chief Executive Officer of EyePoint Pharmaceuticals . Ms. Lurker continued , “ Additionally , we are pleased that customer demand for our commercial products , DEXYCU and YUTIQ has continued to grow this quarter with DEXYCU setting an all - time high of approximately 10,900 units , a 404 % increase from Q2 2020. This momentum has driven year - to - date net product revenues for both products significantly ahead of 2020 and we continue to see solid customer demand for both products into the third quarter . ” R & D Highlights In July 2021 , the Company reported positive 30 - day safety results for all cohorts from the DAVIO trial of EYP- 1901 for wet - AMD . The DAVIO clinical trial of EYP - 1901 enrolled 17 wet AMD patients across three dose cohorts . Key safety observations through at least 30 - Day post - dosing follow - up for all patients include no serious adverse events ( SAEs ) , ocular or systemic , no reported adverse events ( AEs ) related to significant intraocular inflammation , best - corrected visual acuity ( BCVA ) reduction , or elevation of intraocular pressure , and no events of endophthalmitis , retinal detachment , or migration into the anterior chamber .